يعرض 1 - 10 نتائج من 154 نتيجة بحث عن '"Freston, James W."', وقت الاستعلام: 1.04s تنقيح النتائج
  1. 1
    دورية أكاديمية
  2. 2
    دورية أكاديمية
  3. 3
    دورية أكاديمية

    المصدر: Regev, Arie; Avigan, Mark I; Kiazand, Alexandre; Vierling, John M; Lewis, James H; Omokaro, Stephanie O; Di Bisceglie, Adrian M; Fontana, Robert J; Bonkovsky, Herbert L; Freston, James W; Uetrecht, Jack P; Miller, Ethan D; Pehlivanov, Nonko D; Haque, Syed Asif; Harrison, Melanie J; Kullak-Ublick, Gerd A; Li, Hewei; Patel, Niti N; Patwardhan, Meenal; Price, Karen D; Watkins, Paul B; Chalasani, Naga P (2020). Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development. Journal of autoimmunity, 114:102514.

    وصف الملف: application/pdf

    العلاقة: https://www.zora.uzh.ch/id/eprint/199961/1/1-s2.0-S0896841120301360-main.pdfTest; info:pmid/32768244; urn:issn:0896-8411

  4. 4
    دورية أكاديمية
  5. 5
    دورية أكاديمية
  6. 6
    دورية أكاديمية
  7. 7
    دورية أكاديمية

    المساهمون: Gastroenterology, IU School of Medicine

    المصدر: PMC

    وصف الملف: application/pdf

    العلاقة: Alimentary Pharmacology & Therapeutics; Regev, A., Palmer, M., Avigan, M. I., Dimick‐Santos, L., Treem, W. R., Marcinak, J. F., … Chalasani, N. (2019). Consensus: guidelines: best practices for detection, assessment and management of suspected acute drug‐induced liver injury during clinical trials in patients with nonalcoholic steatohepatitis. Alimentary Pharmacology & Therapeutics, 49(6), 702–713. https://doi.org/10.1111/apt.15153Test; https://hdl.handle.net/1805/20828Test

  8. 8
  9. 9
    دورية أكاديمية

    المساهمون: Suzuki,A Division of Gastroenterology, Duke University, Durham, North Carolina, USA. Andrade Bellido,RJ Unidad de Hepatología (Hepatology Unit), Grupo de Estudio para las Hepatopatías Asociadas a Medicamentos, Coordinating Center, Hospital Universitario Virgen de la Victoria, Facultad de Medicina, Campus Universitario de Teatinos, Malaga, Spain. Bjornsson,E Department of Internal Medicine, Section of Gastroenterology and Hepatology, Landspitali University Hospital, Reykjavik, Iceland. Andrade Bellido,RJ, Lucena González,MI Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Málaga, Spain. Lucena González,MI Servicio de Farmacología Clínica (Clinical Pharmacology Service), Grupo de Estudio para las Hepatopatías Asociadas a Medicamentos, Coordinating Center, Hospital Universitario Virgen de la Victoria, Facultad de Medicina, Campus Universitario de Teatinos, Málaga, Spain. Lee,WM Division of Digestive and Liver Diseases, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, USA. Yuen,NA, Hunt,CM Global Clinical Safety and Pharmacovigilance, GlaxoSmithKline, Durham, North Carolina, USA. Freston,JW Department of Internal Medicine, University of Connecticut, Farmington, Connecticut, USA., This study has been partially funded by a research grant from the Spanish Medicine Agency, Fondo de Investigacion Sanitaria FIS PI 07/0980 and EC07/90910, and received support from Boehringer-Ingelheim. CIBERehd is funded by Instituto de Salud Carlos III. The ALF Study Group is funded by NIH Grant U-01 DK058369.

    وصف الملف: application/pdf

    العلاقة: http://adisonline.com/drugsafety/pages/articleviewer.aspx?year=2010&issue=33060&article=00007&type=abstractTest; Suzuki A, Andrade RJ, Bjornsson E, Lucena MI, Lee WM, Yuen NA, et al. Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase: unified list based on international collaborative work. Drug Saf. 2010; 33(6):503-22; http://hdl.handle.net/10668/588Test

  10. 10
    دورية أكاديمية